Synthetic data only. Never enter patient information; nothing is sent or stored. For clinicians. Not FDA cleared.For licensed clinicians. Educational demonstration on synthetic data. Never enter real patient identifiers or protected health information: everything runs in your browser and nothing is sent or stored. Clinical decision support only; not FDA cleared; physician review is required.
CPE-006 · Safety
HG-12: Testosterone-therapy monitoring
Testosterone-therapy monitoring. Evaluates on testosterone therapy.
Active rulePriority 2Testosterone engine v1.0.0
Condition
- on testosterone therapy
- hematocrit > 54% (priority) OR hematocrit not checked in the last 12 months OR PSA not checked in the last 12 months (age 40 and over)
What it reports
- Hematocrit above 54% calls for evaluation and a pause in therapy per the Endocrine Society
- Interval prompts for hematocrit and PSA
Diagnostic boundary
- Monitoring prompts, not instructions to adjust therapy.
Evidence
- EV-ES-TRT-2018Bhasin S, Brito JP, Cunningham GR, et al. Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2018;103(5):1715-1744.Supports: Diagnose with symptoms plus unequivocally low testosterone on two morning fasting samples Contraindications and cautions to therapy; monitoring of hematocrit and PSA Evaluation of the type of hypogonadism with LH and FSH
- EV-AUA-2018Mulhall JP, Trost LW, Brannigan RE, et al. Evaluation and Management of Testosterone Deficiency: AUA Guideline. J Urol. 2018;200(2):423-432.Supports: Total testosterone below 300 ng/dL as the threshold; repeat and confirm; fertility counselling before therapy
Cases where this rule fires
Open a case to see this rule fire with real inputs, then change the values until it stops.
Try Biod in your practice
The Clinical Intelligence Layer — transforming fragmented clinical information into structured intelligence for clinician review and action.